| 망막F-012 |
| Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration |
| 연세대학교 의과대학 안과학교실(1), 국제성모병원 안과(2), 차의과대학 분당차병원 안과학교실(3), 제일안과의원(4) |
| 강혜민(1,2), 권희정(3), 이정호(4), 이승규(1), 이성철(1) |
|
목적 : To investigate prognostic implication of subfoveal choroidal thickness measured by enhanced depth imaging optical coherence tomography (EDI OCT) on treatment outcome after intravitreal ranibizumab injections for typical exudative age-related macular degeneration (AMD).
방법 : A total of 40 eyes of 37 patients who completed 6-month follow-up were analyzed retrospectively. Patients' data were retrieved from medical records. Subfoveal choroidal thickness at baseline, 3 months, and 6 months was measured by EDI OCT. Treatment response was evaluated after three monthly intravitreal ranibizumab injections. Responders (responder group) was defined as a 100 µm or more decrease or complete resolution of subretinal fluid, whereas non-responders (non-responder group) were defined as changes less than 100 µm or more than 100 µm increase of subretinal fluid by OCT.
결과 : Mean age at diagnosis was 72.1±8.1years, and 22 eyes(55.0%) were responders. The responder group had thicker subfoveal choroid(257.2±108.3µm) and smaller lesions(1.3±0.8µm) at baseline than the non-responder group(167.1±62.4 µm,P=.003;and 2.0±1.0µm,P=.008). The responder group showed significantly better vision and thicker subfoveal choroid at 3 months(P=.002;and P=.023) and 6 months(P=.004 and P=.031). Stepwise and binary regression analysis demonstrated that subfoveal choroidal thickness was significantly correlated with visual outcome(B=-0.002,P=.003) and treatment response(B=.018)
결론 : Subfoveal choroidal thickness may be a predictive factor for visual outcome and treatment response in typical exudative AMD after intravitreal ranibizumab injections.
|
| |